A Phase I Study of Gemtuzumab Ozogamicin (GO) in Combination with Busulfan and Cyclophosphamide (Bu/Cy) and Allogeneic Stem Cell Transplantation in Children with Poor-Risk CD33 + AML: A New Targeted Immunochemotherapy Myeloablative Conditioning (MAC) Regimen

导出原文传递

翻译打印收藏纠错

作者： Satwani,P. ^[1] ; Bhatia,M. ^[2] ; Garvin,J.H. ^[3] ; George,D. ^[4] ; DelaCruz,F. ^[5] ; LeGall,J. ^[6] ; Jin,Z. ; Schwartz,J. ; Duffy,D. ; vandeVen,C. ; Foley,S. ; Hawks,R. ; Morris,E. ; Baxter-Lowe,L.A. ; Cairo,M.S.

作者单位： Department of Surgery, University of California San Francisco, San Francisco, CA, United States ^[1] Department of Pediatrics, New York Medical College, Valhalla, NY, United States, Department of ^[2] Department of Biostatistics, New York Presbyterian Morgan Stanley Children's Hospital, Columbia ^[3] Department of Pediatrics, New York Medical College, Valhalla, NY, United States ^[4] Department of Pediatric, New York Presbyterian Morgan Stanley Children's Hospital, Columbia ^[5] Depatment of Pathology and Cell Biology, New York Presbyterian Morgan Stanley Children's Hospital ^[6]

关键词 Allogeneic stem cell transplantation AML Conditioning regimen Gemtuzumab ozogamicin Pediatrics

发布时间 2013-11-20

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交